Journals / Ulusal Travma ve Acil Cerrahi Dergisi / 2010 / Cilt: 16 - Sayı: 1

Fournier?s gangrene: analysis of risk factors affecting the prognosis and cost of therapy in 18 cases

Fournier gangreni: 18 olgudaki prognoza etki eden risk faktörlerinin ve tedavi maliyetinin değerlendirilmesi

Pages
71–76
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

FG is a disease that might cause extended hospital stay and high treatment cost.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND Fournier’s gangrene (FG) is a rapidly progressive, polymicrobial, synergistic necrotizing fasciitis, and the mortality rate is still high.
📊
Key Findings & Data:METHODS Eighteen patients operated for FG during 2003-2007 were investigated retrospectively.
💡
Conclusion & Impact:FG is a disease that might cause extended hospital stay and high treatment cost.
🔬Design:Research Article
📍Scope:2003-2007 Verileri
⚙️Variables:Domain Parameters

Abstract

BACKGROUND Fournier’s gangrene (FG) is a rapidly progressive, polymicrobial, synergistic necrotizing fasciitis, and the mortality rate is still high. We aimed to determine the risk factors affecting prognosis and treatment cost. METHODS Eighteen patients operated for FG during 2003-2007 were investigated retrospectively. Surviving and exitus groups were compared regarding demographic data, etiological factors, laboratory findings, treatment modality, length of hospital stay, and treatment cost. RESULTS Mean age was 54.5 years, and the female/male ratio was 6/12. Mortality was observed in 6 (33.3%) patients and was significantly high among females (66.6%) (p=0.035). Mean duration of complaint in the exitus group (9±3 days) was higher than in survivors (5±3 days) (p=0.018). The most frequent comorbid disease was diabetes (39.2%), the most frequent etiology was perianal abscess (55.6%) and the primary location of infection was anorectal region (61.1%). Hyponatremia was significantly high in surviving patients (p=0.039). Mean of FG severity point in the exitus group (6.83) was higher than in survivors (3.17) (p=0.011). The most frequently cultivated microorganism, Escherichia coli (66.6%), was significantly high in the exitus group (p=0.012). The mean number of debridements was 4.67. Fecal diversion was performed in 7 (38.8%) patients. Hospital stay in the surviving group (34.17 days) was higher than in the exitus group (10.50 days) (p=0.002). Treatment cost between groups was indifferent (p>0.05). CONCLUSION Female gender, duration of complaint, FG severity point, and cultivated microorganism (E. coli) were thought to affect mortality. FG is a disease that might cause extended hospital stay and high treatment cost.

Özet

AMAÇ Fournier gangreni (FG) hızlı ilerleyen sinerjistik, polimikrobiyal nekrotizan fasiittir. Hastalığın mortalitesi halen yüksektir. Çalışmamızda hastaların prognozuna etki eden risk faktörlerini ve tedavi maliyetini belirlemeyi amaçladık. GEREÇ VE YÖNTEM 2003-2007 yılları arasında FG nedeniyle ameliyat edilen 18 hastanın dosyaları retrospektif olarak incelendi. Yaşayan ve ölümcül seyreden hasta grupları demografik özellikler, etyolojik faktörler, laboratuvar bulguları ve tedavi uygulamaları yanı sıra hastanede kalış süresi ve tedavi giderleri yönünden karşılaştırıldı. BULGULAR Hastaların yaş ortalaması 54,5 ve kadın/erkek oranı 6/12 idi. Mortalite 6 (%33,3) hastada gözlendi ve kadınlarda (%66,6) anlamlı şekilde fazlaydı (p=0,035). Şikâyet süresi ölümcül seyreden hastalarda (9±3 gün) yaşayanlardan (5±3 gün) fazlaydı (p=0,018). En sık; yandaş hastalık diyabet (%39,2), etyoloji perianal apse (%55,6), enfeksiyonun primer yerleşimi anorektal bölgeydi (%61,1). Hiponatremi yaşayan hastalarda fazlaydı (p=0,039). FG şiddet puanı ortalaması ölümcül seyredenlerde (6,83) yaşayanlardan (3.17) fazlaydı (p=0,011). Hastalarda en sık üreyen bakteri E.coli’ydi (%66,6) ve mortal seyreden hastalarda anlamlı şekilde fazlaydı (p=0,012). Hastaların debridman sayısı ortalaması 4,67 idi. Fekal diversiyon 7 (%38,8) hastaya uygulanmıştı. Hastanede yatış süresi yaşayanlarda (34,17 gün) ölümcül (10,50 gün) olanlardan fazlaydı (p=0,002). Hasta gruplarının tedavi maliyeti farksızdı (p>0,05). SONUÇ Kadın cinsiyeti, tedavi öncesi geçen şikâyetin süresi, FG şiddet puanı ve kültürde üreyen mikroorganizmanın (E. coli) mortaliteyi etkileyebileceği düşünülmektedir. FG tedavi süresi uzun ve maliyeti fazla olabilecek bir hastalıktır.

🔖

Cite This Article

CANBAZ, H., ÇAĞLIKÜLEKÇİ, M., ALTUN, U., DİRLİK, M. M., TÜRKMENOĞLU, Ö., TAŞDELEN, B., AYDIN, S. (2010). Fournier?s gangrene: analysis of risk factors affecting the prognosis and cost of therapy in 18 cases. Ulusal Travma ve Acil Cerrahi Dergisi, Cilt: 16 - Sayı: 1, 71–76. https://ajindex.com/articles/324553

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Eke N. Fournier’s gangrene: a review of 1726 cases. Br J Surg 2000;87:718-28
  2. Vick R, Carson CC 3rd. Fournier’s disease. Urol Clin North Am 1999;26:841-9
  3. Smith GL, Bunker CB, Dinneen MD. Fournier’s gangrene. Br J Urol 1998;81:347-55
  4. Atakan IH, Kaplan M, Kaya E, Aktoz T, Inci O. A lifethreatening infection: Fournier’s gangrene. Int Urol Nephrol 2002;34:387-92
  5. Villanueva-Sáenz E, Martínez Hernández-Magro P, Valdés Ovalle M, Montes Vega J, Alvarez-Tostado F JF. Experience in management of Fournier’s gangrene. Tech Coloproctol 2002;6:5-10; discussion 11-3
  6. Korkut M, Içöz G, Dayangaç M, Akgün E, Yeniay L, Erdoğan O, et al. Outcome analysis in patients with Fournier’s gangrene: report of 45 cases. Dis Colon Rectum 2003;46:649- 52
  7. Jeong HJ, Park SC, Seo IY, Rim JS. Prognostic factors in Fournier gangrene. Int J Urol 2005;12:1041-4
  8. Unal B, Kocer B, Ozel E, Bozkurt B, Yildirim O, Altun B, et al. Fournier gangrene. Approaches to diagnosis and treatment. Saudi Med J 2006;27:1038-43
  9. Yaghan RJ, Al-Jaberi TM, Bani-Hani I. Fournier’s gangrene: changing face of the disease. Dis Colon Rectum 2000;43:1300-8
  10. Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, et al. Fournier’s gangrene: risk factors and strategies for management. World J Surg 2006;30:1750-4
  11. Pawłowski W, Wronski M, Krasnodebski IW. Fournier’s gangrene. [Article in Polish] Pol Merkur Lekarski 2004;17:85-7. [Abstract] 12. Chawla SN, Gallop C, Mydlo JH. Fournier’s gangrene: an analysis of repeated surgical debridement. Eur Urol 2003;43:572-5
  12. Taviloglu K, Cabioglu N, Cagatay A, Yanar H, Ertekin C, Baspinar I, et al. Idiopathic necrotizing fasciitis: risk factors and strategies for management. Am Surg 2005;71:315-20
  13. Norton KS, Johnson LW, Perry T, Perry KH, Sehon JK, Zibari GB. Management of Fournier’s gangrene: an eleven year retrospective analysis of early recognition, diagnosis, and treatment. Am Surg 2002;68:709-13
  14. Akgün Y, Yılmaz G. Fournier gangreninde mortaliteye etki eden faktörler. Ulusal Travma Dergisi 2005;11:49-57
  15. Murat C, Ünlüer E, Toktaş G, Mimaroğlu Ş, Gürbüz C, Serin Y. Fournier Gangreni: 18 olgunun sunumu. Ulusal Travma Dergisi 1999;5:28-30
  16. Erdoğan O, Arıcı C, Çolak T, Yıldız S, Öğüş M, Akaydın M. Nekrotizan yumuşak doku enfeksiyonu ve mortaliteyi etkileyen faktörler. Ulusal Travma Dergisi 1999;5:184-8
  17. Başoğlu M, Gül O, Yildirgan I, Balik AA, Ozbey I, Oren D. Fournier’s gangrene: review of fifteen cases. Am Surg